Home | Welcome to Contract Pharma   
Last Updated Thursday, April 24 2014
Print

Evotec Earns Boehringer Milestone



By Kristin Brooks



Published December 10, 2013
Related Searches: Development Preclinical Clinical Trials Phase I
Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim, triggering a 4.0 million euro payment for the transition of an oncology molecule into preclinical development.
 
Dr. Mario Polywka, chief operating officer of Evotec said, "This is the 21st milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into preclinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec's overall strategy of building up a pipeline of assets of which we have interest in future upside."
 
In 2004, the companies entered into a multi-year, multi-target drug discovery alliance to identify and develop preclinical candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On